News stories about Alphatec Holdings (NASDAQ:ATEC) have trended somewhat positive on Tuesday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alphatec Holdings earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the medical technology company an impact score of 46.9179964647547 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Spine Biologics Market worth USD 525.86 million by 2021 – MarketDataForecast (emailwire.com)
- Alphatec Holdings’ (ATEC) CEO Terry Rich on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Alphatec Holdings, Inc. to Host Earnings Call (finance.yahoo.com)
- Edited Transcript of ATEC earnings conference call or presentation 9-Nov-17 9:30pm GMT (finance.yahoo.com)
- The Positive long-term growth outlook of Spine Biologics Market (reports.pr-inside.com)
Shares of Alphatec Holdings (NASDAQ ATEC) traded up $0.02 on Tuesday, hitting $3.60. The company had a trading volume of 46,500 shares, compared to its average volume of 96,600. The company has a debt-to-equity ratio of -1.11, a current ratio of 2.11 and a quick ratio of 1.08. Alphatec Holdings has a one year low of $1.58 and a one year high of $5.81.
Several analysts have recently commented on the company. Lake Street Capital assumed coverage on Alphatec Holdings in a research note on Monday, October 16th. They issued a “buy” rating and a $7.00 price objective for the company. ValuEngine downgraded Alphatec Holdings from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 17th. Finally, HC Wainwright assumed coverage on Alphatec Holdings in a research note on Monday, August 14th. They issued a “buy” rating and a $4.00 price objective for the company.
Alphatec Holdings Company Profile
Alphatec Holdings, Inc is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures.
Receive News & Ratings for Alphatec Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.